Effect of conjugated linoleic acid, vitamin E and their combination on lipid profiles and blood pressure of Iranian adults with active rheumatoid arthritis by Aryaeian, Naheed et al.
© 2008 Aryaeian et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article 
which permits unrestricted noncommercial use, provided the original work is properly cited.
Vascular Health and Risk Management 2008:4(6) 1423–1432 1423
ORIGINAL RESEARCH
Effect of conjugated linoleic acid, vitamin E and their 
combination on lipid proﬁ  les and blood pressure 
of Iranian adults with active rheumatoid arthritis
Naheed Aryaeian1
Farhad Shahram2
Mahmoud Djalali1
Mohammad R Eshragian3
Abolghasem Djazayeri1
Abdolfatah Sarrafnejad4
Nasim Naderi2
Maryam Chamari1
Fariha Fatehi1
Mahnaz Zarei1
1Department of Nutrition and 
Biochemistry, School of Public 
Health and Institute of Public Health 
Research, Tehran University of Medical 
Sciences, Iran; 2Rheumatology 
Research Center, Shariati Hospital, 
Tehran University of Medical Sciences, 
Iran; 3Department of Epidemiology 
and Biostatistics, School of Public 
Health and Institute of Public Health 
Research, Tehran University 
of Medical Sciences, Iran; 4Department 
of Immunology, School of Public 
Health and Institute of Public Health 
Research, Tehran University 
of Medical Sciences, Iran
Correspondence: Mahmoud Djalali
Department of Nutrition 
and Biochemistry, School 
of Public Health, Tehran University 
of Medical Sciences, Iran
Tel +98 21 8895 4911
Fax +98 21 8897 4462
Email jalalimahmoud@hotmail.com
Abstract: The aim of this study was to assess the impact of conjugated linoleic acids (CLAs), 
vitamin E, and combination of these nutrients on serum lipid proﬁ  les and blood pressure (BP) in 
patients with active rheumatoid arthritis (RA). In a randomized, double-blind, placebo-controlled 
trial, 87 patients with active RA were divided into four groups receiving one of the following 
daily supplements for three months: Group C: CLAs 2.5 g equivalent to 2 g mixture of cis 9-trans 
11 and trans 10-cis12 CLAs in a rate of 50/50; Group E: vitamin E: 400 mg; Group CE: CLAs 
and vitamin E at above doses: Group P: placebo. After supplementation, SBP levels decreased 
signiﬁ  cantly in the group C in comparison with groups E and P and mean arterial pressure 
reduced signiﬁ  cantly in groups C and CE. There weren’t signiﬁ  cant differences in the levels 
of prostaglandin E2 (PGE2), triglycerides, cholesterol, low-density lipoprotein cholesterol 
(LDL-C), high-density lipoprotein cholesterol (HDL-C), LDL/HDL, cholesterol/HDL, fasting 
blood sugar, C-reactive protein (CRP), arylestrase activity, platelet count and body mass index 
between groups. CRP dropped nonsigniﬁ  cantly in groups P, C, E and CE (19%, 24%, 55%, and 
39%, respectively). Erythrocytes sedimentation rate levels decreased in groups C, E and CE 
(P   0.05, P   0.05, P   0.001, respectively). It is concluded that supplementation of CLAs 
decreased BP and vitamin E decreased CRP. Therefore cosupplementation of CLAs and vitamin 
E might be proﬁ  table for heart disease prevention in RA patients.
Keywords: rheumatoid arthritis, lipid proﬁ  les, blood pressure, conjugated linoleic acids, 
vitamin E
Introduction
Rheumatoid arthritis (RA), as the most common inﬂ  ammatory disease, is associated 
with excess cardiovascular morbidity and mortality that is not entirely explained by 
traditional risk factors of cardiovascular disease (CVD) (De Pablo et al 2007). It might 
be due to an increased prevalence of cardiovascular risk factors such as dyslipidemia 
(Nurmohamed 2007). Risk factors for CVD, including inﬂ  ammatory biomarkers, low 
intake of antioxidants, and vitamins, may contribute to excess CVD in persons with RA 
(Dessein et al 2006). There is a complex relationship between inﬂ  ammation, antioxidant 
vitamin status, and the risk of CVD. Furthermore, low intakes of antioxidant vitamins 
and other micronutrients, including vitamin E, have been reported to be inversely 
associated with CVD incidence and mortality (De Pablo et al 2007). Conjugated 
linoleic acids (CLAs) are a group of naturally occurring isomers of linoleic acid that 
differ in the position or geometry of their double bonds (Kelly 2001; Bhattacharya et al 
2006). The biological activities of CLAs have received considerable attention because 
of its anticancer (Parodi 1999), antiatherogenic (Rudel 1999; Arbonés-Mainar et al 
2006) and antidiabetic effects (Peck et al 1998). The atheroprotective properties of 
CLAs have been particularly well documented (Kritchevsky et al 2000; Toomey et al 
2003). Inclusion of CLAs in a hypercholesterolemic diet in rabbits led to a signiﬁ  cant Vascular Health and Risk Management 2008:4(6) 1424
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reduction in serum triglyceride (TG), low-density lipoprotein 
cholesterol (LDL-C) and cholesterol (CHO) levels. In 
addition, there was a reduced incidence of atherosclerotic 
plaque formation in the rabbit aorta (Lee et al 1994). Similar 
results have also been reported for hamster hypercholes-
terolemia models (Nicolosi et al 1997; Wilson et al 2000). 
Despite these ﬁ  ndings, some reports suggest that CLAs may 
possibly have proatherogenic effects (Munday et al 1999; 
Gavino et al 2000). There are several molecular mecha-
nisms for explaining the hypotriacylglycerolemic effect of 
CLAs. The cis-9, trans-11 and the trans-10, cis-12 isomers of 
CLAs are potent peroxisome proliferators-activated receptor 
(PPAR) agonists. PPARα is a key transcription factor that 
regulates hepatic lipid metabolism (Moya-Camarena and 
Belury 1999a). Feeding CLAs-enriched diets increases the 
expression of PPARα-responsive genes in animals (Moya-
Camarena and Belury 1999b). Therefore, the TG-lowering 
effect of CLAs may be partly attributed to the effect of 
CLAs on PPARα. CLAs is also a PPARγ ligand. In adipose 
tissue, PPARγ regulates the expression of the genes that 
determine adipogenesis, lipid metabolism and insulin sensi-
tivity (Lowell et al 1999; Moya-Camarena et al 1999). Some 
other proposed mechanisms include their role on peroxisome 
proliferators-sterol regulatory element-binding proteins 
(SREBPs) (Pai et al 1998) and stearoyl-CoA desaturase 
(SCD) (Miyazaki et al 2000, 2001; Ntambi 1999). SREBP1c 
isoforms regulate fatty acid and TG synthesis (Pai et al 1998). 
Studies suggest that liver SREBP-1c expression is dependent 
on the nuclear hormone liver X receptor (LXR). C9 t11 
isomer was shown to down-regulate mRNA expression of 
LXR-α and SREBP-1c, whereas the t10 c12 isomer had no 
effect (Roche et al 2002). The results suggested that c9t11 
isomer positively inﬂ  uences lipid metabolism by reduced 
synthesis and cleavage of hepatic SREBP-1, which in turn 
is regulated by LXRα expression. SREBP-1c enhances the 
transcription of the genes required for fatty acid synthesis and 
fatty acid elongation including fatty acids synthetase (FAS) 
and SCD (Pai et al 1998; König et al 2008). Hypertension 
is also a common pathological state associated with an 
increased risk of cardiovascular diseases. Some studies have 
shown that CLAs (50:50) or the t10c12 isomer decreases 
blood pressure (BP) and hypertension in various rat models 
prone to develop obesity, diabetes and hypertension (Nagao 
et al 2003a, 2003b; Alice et al 2005). One possible mecha-
nism is through inhibition of cyclooxygenases, both of them 
have been implicated in the development of atherosclerosis 
(Belton et al 2003). c9, t11- and t10, c12-CLAs isomers are 
not substrates for cyclooxygenases (COX) but compete with 
arachidonic acid for access to the enzymes. In one study, it 
was seen that feeding rabbits with an atherogenic diet rich 
in CLAs reduced atherosclerotic lesion sizes (Valetille et al 
2005). A number of studies in rabbits have considered the 
potential for the lipophilic antioxidant vitamin E to inhibit 
atherosclerosis in vitro by decreasing lipid peroxidation of 
LDL (Schwenke et al 1998). Some epidemiological studies 
have shown an association between high dietary intake and 
high serum concentrations of vitamin E and lower rates of 
ischemic heart disease (Gey et al 1990; Rimm et al 1993; 
Stampfer et al 1993) and myocardial infarction (Stephens 
et al 1996). Here, we investigated the effect of 50:50 blend 
of c9, t11: t10, c12-CLAs on BP and lipid proﬁ  les in active 
RA patients.
Materials and methods
Subjects
A randomized double blind placebo controlled trial was 
conducted in a 12 week period in 87 patients with active RA. 
Patients were between 19–69 years old and had RA for at 
least 2 years fulﬁ  lling American College of Rheumatology 
(ACR) criteria of 1987 (Arnett et al 1988). The method for 
evaluation of disease activity was global physician assessment 
(GPA). Disease activity was determined by rheumatologist 
by medical history, pain in joints, morning stiffness, 
inﬂ  ammation and tenderness and by acute phase reactants 
such as C-reactive protein (CRP), erythrocytes sedimentation 
rate (ESR), platelet (PLT), and hemoglobin (Hb). Data on 
dietary habits, dietary supplements, anthropometric indices 
including body mass index (BMI), smoking habits, and 
drug history were obtained by face to face interview. The 
exclusion criteria were: abnormal renal and/or hepatic 
function, smoking, and history of myocardial infarction, 
pregnancy, taking vitamins and/or mineral supplements, 
hyperlipidemia and taking drugs such as thyroid hormones, 
estrogens, progesterone, diuretics or β-blockers. A written 
informed consent was obtained from all participants. The 
research protocol was approved by the Ethics Committee of 
Tehran University of Medical Sciences. The patients were 
divided into four groups to receive randomly either CLAs 
(group C), vitamin E (group E), both CLAs and vitamin E 
(group CE) or placebo (group P). CLAs was prescribed 2 g 
daily as 2 capsules (each capsule was 1.25 g and contained 
80% CLAs) containing both cis-9, trans-11 CLAs and 
trans-10, cis-12 triglyceride type CLAs in equal proportion 
and vitamin E (α-tocopherol, 400 mg). Corn oil was the 
placebo for vitamin E and high oleic sunﬂ  ower (HOSF) was 
placebo for CLAs. These were assigned to one of the four Vascular Health and Risk Management 2008:4(6) 1425
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treatment groups using random permuted blocks procedure. 
The amount of nutrients intakes were estimated using a 
24-hour dietary recall questionnaire for two following days 
before and after the study and analyzing by Food Processor 
software (ESHA Research, Salem, OR).
The subjects were asked not to alter their usual diets and 
physical activity throughout the study and any changes in 
their medication were avoided whenever possible and if the 
patients did change their nonsteroidal anti-inﬂ  ammatory 
drug (NSAIDs) intake they must write it in the special 
forms provided. Compliance with the supplementation was 
assessed by counting the number of capsules used and also 
by measuring changes in the serum vitamin E.
After 12–14 h overnight fasting, 10 ml blood samples 
were collected from each subject at the beginning and at the 
end of the three month trial.
Methods
Blood samples were collected in trace element-free tubes. 
Aliquots of serum were transferred to polystyrene tubes 
which were immediately stored at −70 °C until analysis. 
Prostaglandin E2 (PGE2) was measured by ELISA-
Monoclonal Kit (No 514010.1; Cayman Chemical Co, 
Ann Arbor, MI). Plasma CHO and TG concentrations were 
determined by an enzymatic assay adapted to microtiter plates 
using commercially available kits (Randox Labs, Crumlin, 
North Ireland). High-density lipoprotein cholesterol (HDL-C) 
was determined by Immunoinhibition Colorimetric method 
(EliTech, Seppim SAS Industrial, Sees, France). LDL-C 
was measured by enzymatic colorimetric method (EliTech, 
Seppim SAS Industrial). Fasting blood sugar (FBS) was 
measured by enzymatic colorimetric method (colorimetric). 
CRP values were determined with immunoturbidometric 
assay. In this method CRP gives a complex with polyclonal 
antibody and creates turbidity that has positive relation with 
CRP in sample. Arylestrase activity (AEA) was measured 
by phenylacetate that was used as a substrate to measure 
the AEA. Enzymatic activity was calculated from the molar 
absorptive coefﬁ  cient of the produced phenol, one unit of 
AEA was deﬁ  ned as 1 mmol phenol generated per min 
under the above conditions and expressed as units/l of serum 
(Kushi et al 1996). Serum α-tocopherol was determined by 
high performance liquid chromatography (Sanz and Santa-
Cruz 1986). Hematological analyses were counted by an 
automated blood counter (Beckman Coulter, Miami, FL). 
ESR was measured using an ESR apparatus (Greiner Labor 
Technic GmbH, Germany). The systolic (SBP) and diastolic 
blood pressure (DBP) was measured after ﬁ  ve minutes 
seated rest, the mean of two readings at baseline, and after 
three months of supplementation. Mean arterial pressure 
(MAP) was calculated using this formula (SBP + 2DBP)/3 
(Cywinski 1980).
Statistical analysis
All values are expressed as mean ± standard error of mean. 
Log transformation was used to normalize the distribution 
of CRP. All other variables were normally distributed. 
Differences between four groups were compared by one-way 
analysis of variance (ANOVA) for continuous data and the 
χ2-test for categorical data. Post hoc comparisons were 
performed with Tukey test. Adjustment for differences 
in baselines covariates and changes in variables during 
study were performed by analysis of covariance. A value 
of P   0.05 was considered to be statistically signiﬁ  cant. 
All data were analyzed using SPSS software (SPSS Inc., 
Chicago, IL).
Results
As shown in Table 1, groups were similar with respect to the 
sex, age, duration of RA, BMI, and daily intake of vitamin E at 
the beginning of the study. There were no signiﬁ  cant changes 
in BMI, physical activity, dietary intake or medication during 
the study period (data not shown).
Table 2 shows the serum lipid, lipoprotein concentrations 
and BP before and after supplementation for subjects who 
completed the study. At baseline there were no signiﬁ  cant 
differences between groups by ANOVA. Our study did not 
show any signiﬁ  cant changes in plasma CHO or LDL-C 
concentrations in C and CE groups following three months 
of supplementation. Plasma levels of HDL-C increased 
nonsigniﬁ  cantly in the groups P, C, E, and CE by 0.9%, 
1.23%, 2.35%, and 4.9%, respectively as compared with 
baseline. LDL-C increased in all groups, but this increase was 
signiﬁ  cant in group E compared with baseline. We did not ﬁ  nd 
any signiﬁ  cant change in HDL-C and LDL-C concentrations 
among four groups. Total CHO, CHO/HDL-C and LDL-C/
HDL-C ratios, and TG were not altered signiﬁ  cantly after 
supplementation compared with baseline and between four 
groups. After three months of supplementation in the group C, 
SBP levels reduced signiﬁ  cantly by 8% (117.36 ± 3.80 mmHg 
versus 108.04 ± 3.13 mmHg) (P   0.05) and DBP by 8.5% 
(72.36 ± 2.37 mmHg versus 66.14 ± 1.66 mmHg) (P   0.05). 
The MBP decreased as compared with baseline in groups 
C and CE, 8.3% and 5.66%, respectively (Figure 1). The 
reduction of SBP in group C was signiﬁ  cant compared with 
other groups (P   0.05) (Figure 1).Vascular Health and Risk Management 2008:4(6) 1426
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Table 3 shows the serum PGE2, FBS, CRP concentrations, 
AEA, ESR, WBC, PLT, and BMI before and after supplemen-
tation for subjects who completed the study. At baseline there 
were no signiﬁ  cant differences between groups by ANOVA. 
PGE2 didn’t alter signiﬁ  cantly among groups and in each group 
as compared with baseline (P   0.05). ESR levels decreased 
signiﬁ  cantly in groups C, E, and CE (P   0.05, P   0.05, 
P   0.001, respectively) in comparison with baseline and group 
CE had signiﬁ  cantly lower ESR level than group P (P   0.05). 
CRP decreased nonsigniﬁ  cantly in all groups as compared with 
baseline, after three months of supplementation (Figure 2), but 
this reduction was 55% in group E compared with baseline 
(P  =  0.054). The reduction of WBC in group CE was signiﬁ  cant 
compared with other groups (P   0.05) (Table 3). Platelet count 
decreased nonsigniﬁ  cantly in groups CE, C, and E. BMI and 
FBS changes weren’t signiﬁ  cance in all groups. AEA decreased 
nonsigniﬁ  cantly in Groups E, C, and P (P   0.05) and there 
weren’t signiﬁ  cant differences between 4 groups. Following 
the study Serum levels of α-tocopherol increased signiﬁ  cantly 
in groups C, E and CE as compared with baseline (P   0.05, 
P   0.0001, P   0.0001, respectively) and in groups E and 
CE compared with group P (P   0.0001).
Discussion
In RA disease, chronic systemic inﬂ  ammation may contrib-
ute to the higher incidence of CVD. (Hannawi et al 2007; 
Metosios et al 2007). To our knowledge; this is the ﬁ  rst study 
which investigated the effects of CLAs and its combination 
with vitamin E in human with RA disease. In the present 
study, we didn’t ﬁ  nd any signiﬁ  cant changes in the plasma 
Table 1 Demographic, anthropometric and biological data for the four groups before study (Mean ± SEM)
Variables Placebo (n = 22) Conjugated linoleic acids (CLAs) (n = 22) Vitamin E (n = 21) CLAs + vitamin E (n = 22)
Male/Female 3/19 3/19 4/17 5/17
Age (years) 47.95 ± 2.37 46.23 ± 2.79 49.33 ± 2.59 43.77 ± 12.75
Duration of 
RA(years)
8.89 ± 2.06 9.95 ± 1.79 7.24 ± 1.27 7.64 ± 1.32
BMI (kg/m2) 28.48 ± 0.84 27.18 ± 0.99 27.14 ± 1.03 25.65 ± 0.85
Vitamin E intake 
(mg per day)
7.9 ± 0.53188 8.75 ± 0.51723 7.78 ± 0.78260 8.80 ± 0.76936
Note: There were no signiﬁ  cant differences between groups by ANOVA or Chi-square.
Abbreviation: BMI, body mass index.
Table 2 Levels of lipid proﬁ  le and blood pressure variables in patients with active rheumatoid arthritis before and after three months 
supplementation (Mean ± SEM)
Variables Placebo (n = 22) Conjugated linoleic 
acids (CLAs) (n = 22)
Vitamin E 
(n = 21)
CLAs + Vitamin 
E (n = 22)
TG (mg/dl) before 120.45 ± 11.5 118.45 ± 9.83 120.86 ± 9.34 125.91 ± 9.08
after 124.91 ± 13.03 130.4 ± 18.32 132.47 ± 15.07 126.18 ± 14.28
CHO (mg/dl) before 191.32 ± 9.04 187.05 ± 7.94 191.76 ± 10.68 197.68 ± 8.96
after 198.27 ± 10.56 189.4 ± 9.04 201.76 ± 8.82 193.86 ± 8.92
LDL-C (mg/dl) before 104.14 ± 5.48e 102.32 ± 4.43 103.43 ± 5.51ª 106.36 ± 6.65
after 114.86 ± 7.47 107.05 ± 5.00 114.85 ± 6.17 113.50 ± 6.89
HDL-C (mg/dl) before 49.50 ± 1.94 47.77 ± 2.36 50.38 ± 2.79 47.18 ± 2.31
after 49.95 ± 2.26 48.36 ± 2.06 51.57 ± 1.89 49.50 ± 2.04
LDL/HDL before 2.14 ± 0.12f 2.19 ± 0.094 2.12 ± 0.12 2.37 ± 0.19
after 2.37 ± 0.17 2.33 ± 0.12 2.26 ± 0.12 2.32 ± 0.13
CHO/HDL before 3.93 ± 0.19 3.99 ± 0.14 3.88 ± 0.19 4.36 ± 0.26c
after 4.08 ± 0.23 4.03 ± 0.20 3.89 ± 0.19 3.97 ± 0.17
Notes: There were no signiﬁ  cant baseline differences between groups by ANOVA. Statistically signiﬁ  cant differences between before and after: aP   0.05. Statistically non 
signiﬁ  cant differences between before and after: cP = 0.072. Statistically no signiﬁ  cant differences between before and after: eP =0.086. Statistically no signiﬁ  cant differences 
between before and after: fP = 0.065.
Abbreviations: CHO, cholesterol; HDL-C, high-density lipoprotein-cholesterol; LDL, low-density lipoprotein-cholesterol;   TG, triglycerides.Vascular Health and Risk Management 2008:4(6) 1427
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levels of TG and CHO in any of the studied groups. 
The magnitude of the change in plasma TG concentrations 
in our study is comparable with that achieved following 50:50 
CLAs supplementation in Benito and colleagues’ (2001) 
study. They did not ﬁ  nd any effect on plasma CHO, lipopro-
tein, or TG. Noone and colleagues’ (2002) study did not show 
any modiﬁ  cation of plasma CHO and lipoprotein concentra-
tions in healthy subjects receiving the 50:50 CLAs mix, 
however they showed a decrease in the TG concentration. 
Some other studies showed that trans-10, cis-12 CLAs isomer 
may be the effective hypotriglycerolemic isomer (Gavino 
et al 2000; Lin et al 2001). The TG-lowering effect of CLAs 
may be partly attributed to the effect of CLAs on PPARα. 
Furthermore, CLAs is a PPARγ ligand. In adipose tissue, 
PPARγ regulates the expression of the genes that determine 
adiposeness, lipid metabolism, and insulin sensitivity (House-
knecht et al 1998; Lowell 1999). In our study, there was a 
nonsigniﬁ  cant decrease in CHO in CE group. We used CLAs 
capsules with equal proportions of the cis-9, trans-11 and 
trans-10, cis-12 CLAs in triglyceride form. Recent vitro and 
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Figure 1 Levels of mean arterial pressure before and after three months’ vitamin E and conjugated linoleic acid (CLA) supplementation in patients with active rheumatoid 
arthritis. 
Note: *p   0.05 for CLA group compared with baseline and group P.
Table 3 Levels of blood pressure, oxidative stress variables in patients with active rheumatoid arthritis before and after three months 
supplementation (Mean ± SEM)
Variables Placebo (n = 22) Conjugated linoleic 
acids (CLAs) (n = 22)
Vitamin E 
(n = 21)
CLAs + Vitamin 
E (n = 22)
Mean blood pressure (mmHg) Before 90.54 ± 3.03 87.36 ± 2.64ª 86.81 ± 2.73 84.50 ± 2.48
After 91.89 ± 3.06 80.10 ± 1.93 90.89 ± 3.52 79.71 ± 2.36
Min blood pressure (mmHg) Before 74.72 ± 3.11 72.36 ± 2.37ª 71.81 ± 2.62 70.32 ± 2.39
After 75.72 ± 2.78 66.14 ± 1.66 75.24 ± 2.95 65.27 ± 2.37
Max blood pressure (mmHg)† Before 122.18 ± 3.67 117.36 ± 3.80ª 116.8 ± 3.83 113.32 ± 3.25
After 124.68 ± 4.19 108.04 ± 3.13 122.2 ± 5.52 108.59 ± 2.97
Aryl esterase activity (IU/ml) Before 155.05 ± 10.68 159.45 ± 10.12 152.76 ± 8.47 146.77 ± 8.23
After 147.64 ± 8.02 157.55 ± 11.58 140.14 ± 7.23 148.14 ± 11.51
PGE2 Before 607.91 ± 22.76 623.27 ± 21.87 593.81 ± 23.99 620.04 ± 20.34
After 607.82 ± 18.08 613.45 ± 92.06 577.47 ± 18.49 605.04 ± 18.53
Serum vitamin E (μg/ml) Before 4.83 ± 0.81 4.72 ± 0.94a 5.24 ± 0.63b‡ 6.64 ± 0.99bψ
After 5.03 ± 0.79 5.51 ± 0.95 6.63 ± 0.92 7.78 ± 0.98
Notes: There were no signiﬁ  cant baseline differences between groups by ANOVA. Statistically signiﬁ  cant differences between before and after: aP   0.05; bP   0.001, after 
supplementation; †Group C had signiﬁ  cantly lower levels than group P and E (P   0.05); ‡E Group had signiﬁ  cantly higher levels than P group (P   0.01).ψCE Group had 
signiﬁ  cantly higher levels than P group (P   0.05).
Abbreviation: PGE2.Vascular Health and Risk Management 2008:4(6) 1428
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animal studies suggest that the individual CLAs isomers may 
have different effects on lipid metabolism. Human studies 
regarding CHO-related parameters were not in line with the 
animal ones. The inconsistency of results may arise from the 
effects of particular CLAs consists the usual CLAs mix. 
Moreover, the dose of CLAs mix administered to humans, 
on a weight basis, was much lower than that for animal 
models and may not reach the effective level (Smedman and 
Vessby 2001). However, the effects of the CLAs-enriched 
dairy products on blood lipids were more complex. In our 
study similar to Desroches and colleagues’ (2005) study after 
the consumption of the CLAs supplements, LDL-C, and 
HDL-C concentrations and the ratio of total to HDL-C and 
LDL-C to HDL-C were not signiﬁ  cantly changed. Singhal 
and colleagues (2001) study results in patients with coronary 
heart disease were similar to our study and plasma 
TG concentration didn’t change signiﬁ  cantly in the vitamin 
E-supplemented group. A large base of epidemiological 
evidence suggests that a 1 mg/dl increment in HDL-C would 
be associated with a 2%–3% decrement in CVD risk (Gordon 
et al 1989). Our data show that supplementation of vitamin E 
and its combination with CLAs for at least three months can 
increase HDL-C nonsigniﬁ  cantly by 3.4% and 4.5%, respec-
tively. Separate supplementation of CLAs did not improve 
serum HDL-C levels. The absence of such effects of CLAs 
supplementation should not be attributed to the interference 
of weight, physical activity, dietary intake or medication 
because these variables did not change during the study period 
and the patients had good compliance in taking their supple-
ments. α-Tocopherol possibly has power to inhibit oxidation 
induced by α-tocopheroxyl radical (Singh et al 2005) and 
known synergistic action between vitamin E and CLAs (Kim 
et al 2005; Santoz-Zago et al 2007). Other studies have also 
shown that CLAs supplementation had no effect on HDL 
lipid composition (Nicolosi et al 1997; Gavino et al 2000; 
Stangl 2000). In our study, LDL-C increased in all groups 
and the difference between groups was not signiﬁ  cant. Nico-
losi and colleagues (2004) also showed that non-HDL-C 
concentrations were reduced by (9%–13%) in response to a 
CLAs-enriched diet. The LDL-C/HDL-C was reduced in the 
80:20 CLAs group (27.2%) and the 50:50 CLAs group 
(22.4%), however these weren’t signiﬁ  cant (Nicolosi et al 
2004). In our investigation, CLAs plus vitamin E was more 
effective than CLAs in reducing LDL-C/HDL-C, CHO/
HDL-C, and CRP. In the present study, FBS didn’t change 
signiﬁ  cantly in four groups. Few studies have evaluated the 
effect of CLAs intake on glucose metabolism and insulin 
sensitivity in humans, but the available data suggest that 
glucose metabolism may be negatively affected by CLAs 
isomers. In Riserus and colleagues’ (2001) study, a signiﬁ  cant 
increase in glucose levels was observed in both the CLAs 
and the control group. The increase was more pronounced in 
the control group (Riserus et al 2001). In another study, 
glucose levels increased signiﬁ  cantly only in the group receiv-
ing the trans10 cis 12 isomer and not in the case of a mixture 
of different isomers. The increase was not signiﬁ  cantly dif-
ferent from that which occurred in the control group (Riserus 
et al 2002). Smedman and Vessby (2001) also showed an 
increase (p = 0.054) in glycemia after the consumption of a 
mixture of CLAs isomers compared with the control group. 
They observed that insulin levels tended to increase after an 
intake of 2 g CLAs (Smedman and Vessby 2001). Several 
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Figure 2 Levels of C-reactive protein (CRP) before and after three months vitamin E and conjugated linoleic acid (CLA) supplementation in patients with active rheumatoid 
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other studies have shown no deleterious effects on glucose 
or insulin levels or sensitivity to insulin attributable to the 
consumption of different doses of CLAs enriched with cis 9, 
trans 11 or trans 10, cis 12 (Tricon et al 2004; Taylor and 
Zahradka 2004). Results on the effect of CLAs on glu-
cose metabolism from animal studies are controversial 
(Houseknecht et al 1998; Stangl 2000; Tsuboyama-Kascoke 
et al 2000). In our study, CLAs supplementation had no effect 
on body weight. This ﬁ  nding is in agreement with Zambell 
and colleagues (2000) who found no changes in body weight 
or body composition attributed to CLAs supplementation in 
human subjects. However some studies have reported that 
CLAs supplementation (4 g/d) had no effect on body weight, 
but they signiﬁ  cantly reduced body fat (Smedman and Vessby 
2001). It was shown that, 9c, 11t-CLAs, 10t, 12c-CLAs 
inhibited arachidonic acid and collagen-induced platelet 
aggregation (Truitt et al 1999). In the present study, the 
number of platelet decreased nonsigniﬁ  cantly in groups P, 
C, and CE. Leonard and colleagues (2007) studied the effects 
of vitamin E (400 IU) on cholesterol levels of hypercholes-
terolemic patients receiving statins. Similar to our study they 
didn’t ﬁ  nd signiﬁ  cant differences in any lipoprotein choles-
terol fraction. However, unlike our study, a 6% decrease in 
HDL-C was detected within the vitamin E group (p   0.05) 
(Leonard et al 2007). Following our study, LDL-C increased 
in all groups, but this increase was only signiﬁ  cant in group E. 
This increase may be due to increasing the size of LDL-C or 
changing its fractions or by increase of its half life by decreas-
ing LDL-C oxidation. In our study AEA, decreased nonsig-
niﬁ  cantly in groups E, P, and C, but decreased as compared 
with baseline in group E (P = 0.068). We had nonsigniﬁ  cant 
differences between four groups. In one study on pedigreed 
baboons, dietary vitamin E improved LDL quality and 
showed two apparently paradoxical effects on HDL metabo-
lism: lower HDL2 and higher apo A-I. These effects have 
contrasting associations with CVD risk and may help account 
for the mixed results from clinical trials of dietary vitamin 
E. In our study, nonsigniﬁ  cant reductions in serum AEA of 
lipoprotein-associated enzymes, Paraxonase1 (PON1) in all 
groups except group CE was shown. The presence of PON1 
on HDL particles is considered to be a major source of pro-
tection from lipoprotein oxidation. Therefore, reduction of 
PON1 activity may be considered to be prooxidant and pro-
atherogenic (Rainwater et al 2007). Our results contradict 
results in rabbits and humans (Jarvik et al 2002; Jeon et al 
2005). This discrepancy may reﬂ  ect differences in HDL size 
and composition properties among the species. Alternately, 
vitamin E-associated reduction in oxidative stress and 
oxidized LDL may have lowered the metabolic requirements 
for these enzymes to maintain the redox balance in the 
circulation. Then, through feedback mechanisms, the expres-
sion of PON1 may have been downregulated (Jarvik et al 
2003; Rainwater et al 2005). Furthermore the differences 
between groups wasn’t signiﬁ  cant. Following of our study 
Table 4 Levels of FBS, inﬂ  ammation variables and clinical tests in patients with active RA before and after three months supplementation 
(Mean ± SEM)
Variables Placebo (n = 22) Conjugated linoleic acids 
(CLAs) (n = 22)
Vitamin E 
(n = 21)
CLAs + vitamin 
E (n = 22)
CRP (mg/l) Before 6.44 ± 1.68 7.18 ± 2.16 9.06 ± 3.12 5.23 ± 1.37
After 5.48 ± 1.19 5.46 ± 1.18 4.07 ± 0.99 3.17 ± 0.83
ESR (mm/h) Before 28.36 ± 4.59 26.81 ± 2.38a 40.43 ± 5.72a 28.45 ± 3.68‡c
After 27.04 ± 4.04 19.14 ± 2.16 32.28 ± 5.01 17.77 ± 2.60
FBS (mg/dl) Before 90.18 ± 6.41 78.27 ± 1.95 90.85 ± 8.51 85.68 ± 6.15
After 85.04 ± 5.46 75.86 ± 1.41 78.05 ± 2.41 81.85 ± 3.14
WBC (/UL) Before 8587.72 ± 483.94 7728.57 ± 551.24 7724.76 ± 400.36 9280.95 ± 513.42a
After 7752.95 ± 457.03 8533.33 ± 401.86 10276.2 ± 2373.9 8528.57 ± 491.99
Platelet count 
(*1000/UL)
Before 269.07 ± 16.55 294.38 ± 12.49 300.57 ± 15.85 294.14 ± 16.95
After 278.13 ± 13.77 286.09 ± 13.98 279.86 ± 18.34 280.09 ± 14.96
BMI (kg/m2) Before 27.92 ± 0.78 26.95 ± 0.94 27.14 ± 1.03 25.65 ± 0.85
After 28.66 ± 0.84 27.41 ± 4.49 27.97 ± 1.05 25.94 ± 0.76
Notes: There were no signiﬁ  cant baseline differences between groups by ANOVA. Statistically signiﬁ  cant differences between before and after: aP   0.05; bP   0.01; cP   0.001; 
dP = 0.054.
Abbreviations: BMI, body mass index; CRP, C-reactive protein; ESR erythrocyte sedimentation rate; FBS, fasting blood sugar;   WBC, white blood cells.Vascular Health and Risk Management 2008:4(6) 1430
Aryaeian et al
ESR levels decreased signiﬁ  cantly in the groups C, E, and 
CE compared with baseline (P   0.05 P   0.05, P   0.001, 
respectively). ESR levels in group CE was signiﬁ  cantly lower 
than group P (P   0.05). Vitamin E was reported to regulate 
transcription or activity of a number of genes involved in 
oxidative stress, proliferation, inﬂ  ammation, and apoptosis 
(Dutta and Dutta 2003; Tucker and Townsend 2005; Aldred 
et al 2006). CRP dropped in all groups in comparison with 
baseline, but this decreased more in group E (P = 0.054). The 
reduction of WBC in group CE was signiﬁ  cant compare with 
other groups (P   0.05) (Table 3). PLT count decreased 
nonsigniﬁ  cantly in CE, C, E groups. Consequently CLAs, 
vitamin E, and their combination are useful in reduction of 
inﬂ  ammation. Many studies (Igarashi and Miyazawa 2001; 
Kim et al 2002; Palacios et al 2003; Bergamo et al 2006, 
2007; Santos-Zago et al 2007) show the antioxidant effect of 
CLAs, but several studies performed on healthy and obese 
subjects have observed that CLAs administration is associated 
with an increase in some lipid oxidation and peripheral 
inﬂ  ammation parameters (Riserus et al 2002, 2004; Basu et al 
2000a, 2000b; Smedman et al 2004). One of our aims was 
to investigate the effect of α-tocopherol and CLAs supple-
mentation on BP. BP levels decreased signiﬁ  cantly in the 
group C by 8% and 8.5% for DBP and MAP respectively, 
after three months of supplementation as compared with 
baseline. The reduction of SBP in group C was signiﬁ  cant 
compared with the groups E and P (Table 2). Herrera and 
colleagues (2005) studied healthy primigravidas who had a 
family history of pre-eclampsia and diastolic notch. Calcium-
CLAs supplementation reduced signiﬁ  cantly the incidence 
of pregnancy-induced hypertension (PIH) in the study group 
(P = 0.01). Endothelial dysfunction was also signiﬁ  cantly 
reduced after calcium-CLAs supplementation (Herrera et al 
2005). Herrera and colleagues (2006) in another study on 
healthy primigravidas showed that the incidence of PIH was 
signiﬁ  cantly reduced in women receiving the CLAs supple-
ment compare with the placebo. There were no signiﬁ  cant 
differences in the plasma concentrations of ionized calcium, 
PE2 (similar to our study), renin, angiotensin II, parathor-
mone, and calcitonine (Herrera et al 2006). In Raff and col-
leagues’ (2006) investigation, a diet rich in CLAs didn’t alter 
SBP, DBP and pulse pressure, but this may be due to the 
short time for the study (ﬁ  ve weeks). Nagao and colleagues 
(2003a) found that the relative mRNA expressions of angio-
tensinogen and leptin were suppressed by 10t, 12c-CLAs in 
adipose tissue. They speculate that the antihypertensive effect 
of 10t, 12c-CLAs can be attributed to the lowered secretion 
of hypertensive adipocytokines from abdominal adipose 
tissues (Nagao et al 2003a). In another study Nagao and 
colleagues (2003b) showed that CLAs suppresses the devel-
opment of nonobese essential hypertension in spontaneously 
hypertensive rats (SHRs). They concluded that the antihy-
pertensive effect of dietary CLAs may be due to the increase 
of plasma adiponectin level and is associated with the alle-
viation of membrane abnormality in SHRs (Nagao et al 
2003b). In our study in group E, BP increased nonsigniﬁ  -
cantly, in Ward and colleagues’ (2007) study BP, pulse 
pressure, and heart rate increased versus placebo.
Conclusion
It is concluded that supplementation of 2 g CLAs 50:50 mix, 
and its combination with vitamin E for 12 weeks didn’t change 
lipid proﬁ  les and FBS signiﬁ  cantly, but CLAs decreased 
BP and vitamin E decreased CRP so co-supplementation of 
CLAs and vitamin E could be helpful for heart disease 
prevention in RA patients.
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